Metropolis Healthcare Q1 Results: Net profit rises 25.7% YoY to ₹569 million
Metropolis Healthcare reported a 25.7% YoY rise in consolidated net profit to ₹568.83 million for Q1FY26, driven by a 16.6% increase in revenue to ₹4,502.15 million. The Board approved the results and noted a two-month delay in transferring its External Quality Assessment Services Business to a subsidiary. Standalone net profit rose 42.2% YoY to ₹505.83 million.
*this image is generated using AI for illustrative purposes only.
Metropolis Healthcare reported a consolidated net profit of ₹568.83 million for the quarter ended June 30, 2026, up 25.7% from ₹452.45 million in the same period last year. Revenue from operations increased 16.6% year-on-year to ₹4,502.15 million, reflecting continued expansion in its pathology services business. The company’s standalone net profit for the quarter stood at ₹505.83 million, compared to ₹355.82 million in Q1FY25.
The Board of Directors, meeting on August 04, 2026, approved the unaudited standalone and consolidated financial results pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee on the same date and subjected to a limited review by the statutory auditors, B S R & Co. LLP. The Board also noted that the sale and transfer of the External Quality Assessment Services Business to Metropolis Quality Solutions Private Limited, a wholly owned subsidiary, is now expected to take an additional two months beyond the original six-month timeline set in the February 04, 2026 Business Transfer Agreement.
Financial Performance
Consolidated revenue from operations reached ₹4,502.15 million, up from ₹3,860.63 million in Q1FY25. Total expenses rose to ₹3,776.05 million from ₹3,323.49 million in the prior year period. Employee benefits expense, the largest cost component, increased to ₹1,069.76 million from ₹922.79 million. Other expenses stood at ₹1,386.15 million, up from ₹1,193.04 million. The company recorded a profit before tax of ₹777.12 million, compared to ₹612.30 million in Q1FY25.
| Metric | Q1FY26 (₹ million) | Q1FY25 (₹ million) | YoY Change |
|---|---|---|---|
| Revenue from operations | 4,502.15 | 3,860.63 | 16.6% |
| Total expenses | 3,776.05 | 3,323.49 | 13.6% |
| Profit before tax | 777.12 | 612.30 | 27.0% |
| Net profit | 568.83 | 452.45 | 25.7% |
Standalone revenue from operations was ₹3,722.84 million, up from ₹3,232.69 million in Q1FY25. Standalone profit before tax was ₹663.76 million, compared to ₹473.84 million in the prior year. Basic earnings per share for the consolidated entity were ₹2.73, up from ₹2.17 in Q1FY25.
Operational Updates
The company continues to operate under a single reportable segment: Pathology service. During the quarter, the Nomination and Remuneration Committee approved the grant of 14,236 Restricted Stock Units (RSUs) under the Metropolis Restrictive Stock Unit Plan — 2025 and 2,12,345 Employee Stock Options under the Metropolis Employees Stock Option Plan — 2025. Additionally, 4,200 RSUs were allotted under the Metropolis Restrictive Stock Unit Plan — 2020.
The financial results reflect the impact of three business acquisitions completed in FY25: Dapic Metropolis Healthcare Private Limited (₹346.10 million), Scientific Metropolis Pathology Private Limited (₹645.00 million), and Dr. RS Patil's Ambika Pathology Laboratory (₹170.00 million). These acquisitions have been fully integrated into the consolidated results for Q1FY26.
What the Numbers Show
Revenue growth outpaced expense growth, leading to an expansion in pre-tax margins. Consolidated profit before tax grew 27.0% YoY, slightly higher than the 16.6% revenue growth, indicating operational leverage. However, employee benefits and other expenses saw significant increases, suggesting rising input costs or wage pressures. The delay in the External Quality Assessment Services Business transfer may impact short-term operational efficiency but keeps the business within the consolidated group structure longer than initially planned.
Historical Stock Returns for Metropolis Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.00% | +1.24% | +5.13% | +22.77% | +14.57% | -20.68% |
How will the two-month delay in transferring the External Quality Assessment Services Business impact Metropolis Healthcare's short-term consolidated revenue and operational efficiency?
Given the 16% rise in employee benefits expenses, what strategies is the company implementing to manage wage inflation while maintaining its service quality and growth trajectory?
To what extent will the fully integrated FY25 acquisitions contribute to organic-like growth in Q2FY26, and are there plans for further M&A activity to sustain this expansion?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
